This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (43) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Deitcher, S. R. Articles by Fareed, J. Search for Related Content PubMed PubMed Citation Articles by Deitcher, S. R. Articles by Fareed, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Thinners Cancer Hazardous Substances DB WARFARIN Social Bookmarking                         What's this?

Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day Period

Section of Hematology and Coagulation Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, sdeitcher{at}nuvelo.com

Craig M. Kessler, MD

Lombardi Cancer Center, Georgetown University Medical Center, Washington, District of Columbia

Geno Merli, MD

Division of General Internal Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania

James R. Rigas, MD

Division of Hematology and Medical Oncology, Dartmouth Medical School, Lebanon, New Hampshire

Roger M. Lyons, MD

U.S. Oncology, San Antonio, Texas

Jawed Fareed, PhD

Loyola University Medical Center, Maywood, Illinois

This study evaluated enoxaparin alone versus initial enoxaparin followed by warfarin in secondary prevention of venous thromboembolic events in adults with active malignancy. Cancer patients (n = 122) with acute symptomatic venous thromboembolic events were randomly allocated to receive subcutaneous enoxaparin 1.0 mg/kg every 12 hours for 5 days, followed by 1.0 mg/kg daily (group 1a) or 1.5 mg/kg daily (group 1b) for 175 days, or subcutaneous enoxaparin 1.0 mg/kg every 12 hours for at least 5 days and until a stable international normalized ratio of 2 to 3 was achieved on oral warfarin begun on day 2 and continued to day 180 (group 2). There were no significant differences in major and minor bleeding rates between treatment groups. No bleeding events were intracranial or fatal. Enoxaparin treatment was feasible, generally well tolerated, and effective for a 180-day period in the secondary prevention of venous thromboembolic events in patients with active malignancy.

Key Words: Enoxaparin • Deep venous thrombosis • Malignancy

Clinical and Applied Thrombosis/Hemostasis, Vol. 12, No. 4, 389-396 (2006)
DOI: 10.1177/1076029606293692


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. A. Khorana, M. B. Streiff, D. Farge, M. Mandala, P. Debourdeau, F. Cajfinger, M. Marty, A. Falanga, and G. H. Lyman Venous Thromboembolism Prophylaxis and Treatment in Cancer: A Consensus Statement of Major Guidelines Panels and Call to Action J. Clin. Oncol., October 10, 2009; 27(29): 4919 - 4926. [Abstract] [Full Text] [PDF]

				A. Y.Y. Lee Anticoagulation in the Treatment of Established Venous Thromboembolism in Patients With Cancer J. Clin. Oncol., October 10, 2009; 27(29): 4895 - 4901. [Abstract] [Full Text] [PDF]

				A. A. Khorana Cancer and thrombosis: implications of published guidelines for clinical practice Ann. Onc., October 1, 2009; 20(10): 1619 - 1630. [Abstract] [Full Text] [PDF]

				E. A Nutescu, S. A Spinler, A. Wittkowsky, and W. E Dager Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings Ann. Pharmacother., June 1, 2009; 43(6): 1064 - 1083. [Abstract] [Full Text] [PDF]

				B. BABU and T. L. CARMAN Cancer and clots: All cases of venous thromboembolism are not treated the same Cleveland Clinic Journal of Medicine, February 1, 2009; 76(2): 129 - 135. [Abstract] [Full Text] [PDF]

				A. Y.Y. Lee Treatment of Venous Thromboembolism in Patients with Cancer ASCO Educational Book, January 1, 2009; 2009(1): 331 - 336. [Abstract] [Full Text] [PDF]

				P. Prandoni, J. Trujillo-Santos, T. Surico, F. D. Valle, A. Piccioli, M. Monreal, and for the RIETE Investigators Recurrent thromboembolism and major bleeding during oral anticoagulant therapy in patients with solid cancer: findings from the RIETE registry Haematologica, September 1, 2008; 93(9): 1432 - 1434. [Full Text] [PDF]

				A. Falanga, A. Y. Y. Lee, M. B. Streiff, and G. H. Lyman Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer ASCO Educational Book, January 1, 2008; 2008(1): 258 - 268. [Abstract] [Full Text] [PDF]

				G. H. Lyman, A. A. Khorana, A. Falanga, D. Clarke-Pearson, C. Flowers, M. Jahanzeb, A. Kakkar, N. M. Kuderer, M. N. Levine, H. Liebman, et al. American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer J. Clin. Oncol., December 1, 2007; 25(34): 5490 - 5505. [Abstract] [Full Text] [PDF]